Pemetinib/pemetinib purchase price and medication guide

Pemigatinib (Pemigatinib) is an FGFR inhibitor that has attracted much attention in recent years. It is mainly used for the precision treatment of some advanced or recurrent cholangiocarcinoma (CCA) . In China, pemetinib is already on the market, but it has not yet been included in the medical insurance catalog. Therefore, patients have a relatively large financial burden when purchasing the drug. Currently, common specifications in the domestic market include 4.5 mg 14 tablets and 9 mg 14 tablets in two packaging formats. The price of a single box is approximately RMB 20,000 to RMB 50,000. The specific cost will vary depending on channels, hospital procurement conditions and policy adjustments. In comparison, it is also sold in overseas markets. For example, the price of 13.5mg*14 tablets per box may be as high as more than 70,000 yuan, and it is also affected by exchange rate fluctuations, so the cost of cross-border drug purchases is often higher.

It is worth noting that some countries and regions have allowed generic versions of pemetinib to be marketed, such as products in the Southeast Asian market. Among them, the generic version produced by Lucius Pharmaceuticals in Laos has more advantages in price, such as4.5mg*14 tablets are priced at about 700 yuan, which is much lower than the original drug, and the ingredients and dosage standards are the same. This undoubtedly provides a new choice for some patients with greater financial pressure. However, when purchasing generic drugs, patients need to pay attention to the formality of the source channels to ensure drug quality and safety.

In terms of medication guidelines, pemetinib is an oral small molecule drug, and patients need to take it on time under the guidance of a doctor. Since its main mechanism of action is to inhibit the FGFR pathway, common adverse reactions may involve increased blood phosphorus levels. Therefore, it is recommended to monitor blood indicators during medication and follow the principles of a low-phosphorus diet. In addition, patients should avoid stopping the drug without authorization or adjusting the dose on their own, as the stability of drug concentration is critical to efficacy. For patients who are considering cross-border drug purchase, they need to take into account doctor's advice, economic status and channel legitimacy to ensure that the treatment is both scientific and sustainable.

Reference materials:https://go.drugbank.com/drugs/DB15102